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Tumorigenesis and Neoplastic Progression
Semaphorin 3E Expression Correlates Inversely with
Plexin D1 During Tumor Progression
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Plexin D1 (PLXND1) is broadly expressed on tumor
vessels and tumor cells in a number of different human
tumor types. Little is known, however, about the poten-
tial functional contribution of PLXND1 expression to
tumor development. Expression of semaphorin 3E
(Sema3E), one of the ligands for PLXND1, has previ-
ously been correlated with invasive behavior and me-
tastasis, suggesting that the PLXND1-Sema3E interaction
may play a role in tumor progression. Here we investi-
gated PLXND1 and Sema3E expression during tumor
progression in cases of melanoma. PLXND1 was not
expressed by melanocytic cells in either naevi or mela-
nomas in situ, whereas expression increased with in-
vasion level, according to Clark’s criteria. Furthermore,
89% of the metastatic melanomas examined showed
membranous PLXND1-staining of tumor cells. Surpris-
ingly, expression of Sema3E was inversely correlated
with tumor progression, with no detectable staining in
melanoma metastasis. To functionally assess the effects
of Sema3E expression on tumor development, we over-
expressed Sema3E in a xenograft model of metastatic
melanoma. Sema3E expression dramatically decreased
metastatic potential. These results show that PLXND1
expression during tumor development is strongly cor-
related with both invasive behavior and metastasis, but
exclude Sema3E as an activating ligand. (Am J Pathol
2008, 173:1873–1881; DOI: 10.2353/ajpath.2008.080136)
Cutaneous melanoma is a highly malignant tumor derived
from pigment-producing melanocytes in the epidermis.
Melanoma frequently develops in a sequence of steps
from benign proliferative naevi to atypical naevi, nonin-
vasive in situ melanomas (lesions confined to the epider-
mis), invasive melanomas, and finally to metastases. Clin-
ically, melanomas begin as pigmented lesions that
enlarge along an imaginary radius of an imperfect circle,
the so-called radial growth phase.1 At the time of diag-
nosis many melanomas have progressed to the next
phase of progression, or vertical growth phase, which is
characterized by invasion of the papillary and reticular
dermis.1 Whereas the relatively indolent radial growth
phase melanomas rarely give rise to metastases, vertical
growth phase melanomas do have the tendency to me-
tastasize.2 Furthermore, progression from radial growth
phase to vertical growth phase melanoma is accompa-
nied by angiogenesis.3,4 Stage of disease is usually de-
termined histopathologically by both the maximum verti-
cal tumor thickness (Breslow index) and tumor invasion
level (Clark classification).5
Many studies have focused on the identification of
differentiation markers to distinguish naevi from melano-
mas. These include mostly nonspecific markers related to
cell survival, cell adhesion, and extracellular matrix
changes,6–9 general processes that contribute to tumor
growth and metastasis.
Plexins encode large transmembrane proteins that are
receptors for neuropilins and semaphorins, a family of
secreted or membrane-associated proteins.10,11 Class 3
semaphorins have been mostly studied in the developing
nervous system, where they regulate axonal guidance via
activation of plexin/neuropilin complexes.12–15 The wide-
spread expression of both plexins and semaphorins dur-
ing embryogenesis, including outside the nervous sys-
tem, suggests a more general role in physiological and
pathological processes.16,17 We have previously demon-
strated that Plexin D1 (PLXND1) is expressed by vascular
endothelial cells during developmental angiogenesis.18
Loss of PLXND1 function in mice and zebrafish leads to
lethality due to maldevelopment of the cardiovascular
system, indicating a functional role of PLXND1 in vascular
patterning.19,20 Recently, we have shown that PLXND1 is
also specifically expressed on vascular endothelium dur-
ing tumor-associated angiogenesis of primary and met-
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astatic tumors, in both animal tumor models and a num-
ber of human brain tumors.21 Interestingly, in the
examined metastatic brain tumors, including a melanoma
metastasis, we observed abundant specific expression
of PLXND1 on tumor cells too.21 PLXND1 contains in its
intracellular domain consensus motifs for Rho-guanine
nucleotide exchange factors. Therefore, PLXND1 activa-
tion may be predicted to induce cytoskeletal rearrange-
ments, translating into cellular migration and invasion.
These processes are fundamental in both angiogenesis
and tumor metastasis, suggesting that PLXND1 is func-
tionally involved in tumor development in multiple ways.
Three candidate ligands for PLXND1 have been iden-
tified. Semaphorin 3C (Sema3C) binds with high affinity to
a Neuropilin-1/PLXND1 complex,19 whereas binding of
semaphorin 3E (Sema3E) or semaphorin 4A (Sema4A) to
PLXND1 does not require the presence of neuropilin.22,23
Interestingly, Sema3E was identified from array analyses
as a protein involved in tumor invasion, progression, and
metastasis.24 Collectively, these data suggest an involve-
ment of a PLXND1/Sema3E complex in tumor angiogen-
esis, tumor cell invasion, and metastasis.
Here we have addressed this hypothesis in two indepen-
dent ways. First, we analyzed PLXND1 and Sema3E ex-
pression by immunohistochemistry on a series of cutaneous
melanocytic lesions representing different stages of mela-
noma progression. Secondly, we examined the effects of
overexpression of Sema3E in a melanoma metastasis
model. Our results show that PLXND1 expression correlates
with tumor invasion level and metastasis in a melanoma
progression series. In contrast, Sema3E expression showed a
negative association with melanoma progression. This in-
verse correlation was corroborated in functional studies,
which revealed that Sema3E expression, in contrast to
Sema3C, resulted in an altered tumor vascular phenotype
and significantly reduced metastatic potential.
Materials and Methods
Tissue Samples
Formalin-fixed, paraffin-embedded tissue specimens
were obtained from the archive of the Department of
Pathology of the Radboud University Nijmegen Medical
Centre. This study included naevocellular naevi (n  19),
dysplastic naevi (n  10), melanomas in situ (n  5),
primary cutaneous melanomas (n  22), and dissemi-
nated melanomas, including skin (n  4), lymph node
(n  9), brain (n  5), and lung (n  1) metastases. All
primary melanomas were classified by qualified patholo-
gists and graded according to Clark’s criteria (II, n  7;
III, n  5; IV, n  10) and Breslow thickness.
Immunohistochemistry
Tissue sections (4 m) were dewaxed and endogenous
peroxidase activity was quenched with 3% H2O2 in PBS.
Antigen retrieval was performed by digestion with pro-
nase for 9 minutes at 37°C. Subsequently, tissues were
pre-incubated with normal horse serum to block nonspe-
cific binding sites, followed by incubation for 1 hour with
single domain antibody A12, which was previously se-
lected against a PLXND1-specific peptide.21 Single do-
main antibodies were detected by sequential incubations
with the mouse monoclonal anti-VSV antibody P5D4, biotin-
ylated anti-mouse IgG (Vector, Burlingame, CA), and avi-
din-biotin peroxidase complex (Vector) for 1 hour, 30 min-
utes, and 45 minutes respectively. Peroxidase was
visualized by the 3-amino-9-ethylcarbazole (ScyTek, Lo-
gan, UT) peroxidase reaction and sections were counter-
stained with hematoxylin. All incubations were performed at
room temperature.
Fifty of the 75 human melanocytic lesions analyzed for
PLXND1 expression were immunostained for Sema3E
according to standard protocols. In short, antigen re-
trieval was performed by boiling in 10 mmol/L citrate
buffer. Nonspecific binding sites were blocked by incu-
bation with normal horse serum. Slides were incubated
overnight at 4°C with goat anti-Sema3E (Abcam Limited,
Cambridge, UK), and subsequently detected by sequen-
tial incubations with biotinylated anti-goat IgG antibody
(Vector) and avidin-biotin peroxidase complex (Vector).
For immunohistochemical analysis of experimental tu-
mors, tissues (tumor, lung) were formalin-fixed and used for
(immuno)histological analysis using rat anti-mouse CD34
(Hycult Biotechnology, Uden, The Netherlands), rabbit anti-
mouse Ki-67 (Dianova, Hamburg, Germany), rabbit anti-
laminin (Dako, Glostrup, Denmark), rabbit anti-GFP (a kind
gift of Huib Croes, Department of Cell Biology, Radboud
University NijmegenMedical Center, The Netherlands), and
mouse anti-thrombospondin (Abcam Limited) antibodies.
To examine metastatic deposits in lungs of mice carrying
subcutaneous tumors, lungs were cut in five to six slices
and arranged in tissue blocks in such a way that in one
section a representative overview through the lungs is ob-
tained. Numbers of metastases were counted in H&E
stained sections. Differences in metastatic load between
tumor groups were studied usingMann-WhitneyU-test. Sta-
tistics were performed using SPSS software (SPSS Inc,
Chicago, IL).
Cell Lines and Transfections
Mel57 human melanoma cells were cultured in Dulbecco’s
modified Eagles’ medium (Cambrex Bioscience, Ver-
viers, Belgium) supplemented with 10% fetal calf serum
(Cambrex), 100 U/ml penicillin, and 100 g/ml strepto-
mycin (Cambrex) at 37°C at 5% CO2. cDNA encoding
vascular endothelial growth factor (VEGF)-A165 (human
origin) was cloned in pIREShyg essentially as de-
scribed.25 Human Sema3E cDNA was obtained by reverse
transcription polymerase chain reaction (RT-PCR) on glio-
blastoma RNA, using primers HpaI-Sema3E (5-CGTTAA-
CAGGGCTTGGACGG-3) and BstX1-Sema3E (5-CCAG-
CACACTGGTCAGGAGTCCAGCGT-3) and cloned in the
EcoRV/BstXI sites of vector pIRESneo (Clontech, Palo Alto,
CA) to generate plasmid pIRESneoSema3E. In parallel,
Sema3C was PCR cloned in pIRESneo. Mel57 melanoma
cells, stably transfected with pIREShyg-VEGF-A165 were
supertransfected with plasmid pIRESneoSema3E or
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pIRESneoSema3C using Fugene reagent (Roche, Alm-
ere, The Netherlands). Two days after transfection, cells
were put under hygromycin and neomycin selection
pressure until colonies could be expanded. Similarly,
double transfectants of Mel57 were generated express-
ing VEGF-A165 and enhanced green fluorescent protein
(EGFP) as control. The presence of recombinant
VEGF-A, Sema3E, and Sema3C in conditioned medium
was confirmed by Western blot analysis using VEGF-
A20 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), goat anti-Sema3E antibody (Abcam Limited), and
sheep anti-Sema3C antibody (R&D Systems, Oxon,
UK) respectively.
Animals
All animal experiments were approved by the Animal
Experiment Committee of the Radboud University.
Specific pathogen-free, male BALB/c nude mice, 6 to 8
weeks of age were housed under specific pathogen-
free conditions (five mice/cage, temperature 20°C to
24°C; relative humidity 50% to 60%; 15 air changes per
hour; light–dark periods 14 hours/10 hours). Water and
food (RMH, Hope Farms, The Netherlands) were avail-
able to the animals ad libitum.
Metastasis Model
Groups of mice were injected subcutaneously in the flank
with 2 106 Mel57-VEGF-A/Sema3E cells (n 9), Mel57-
VEGF-A/Sema3C cells (n  9), or Mel57-VEGF-A/EFGP
cells (n 8) in 200 l PBS, essentially as described.26 To
be able to analyze mono- or multicellular origin of metas-
tases, we tagged the tumors by co-injecting 4  105
Mel57-EGFP cells. Tumor growth was monitored twice
weekly and volumes calculated as height  depth 
width. Mice were sacrificed after development of severe
cachexia owing to tumor load, which was 28 and 37 days
post subcutaneous injection of Mel57-VEGF-A/EGFP and
Mel57-VEGF-A/Sema3(C/E) cells respectively. One out of
nine animals carrying a Mel57-VEGF-A/Sema3E tumor
had to be sacrificed 2 days earlier because of severe
ascites and tumor deposits on the peritoneum. Before
sacrifice, blood plasma was collected for determination
of circulating VEGF-A levels by an in-house developed
enzyme-linked immunosorbent assay.27
Expression of Extracellular Matrix and Adhesion
Molecules
Total RNA was isolated from 30 frozen 20-m sections of
subcutaneous Mel57-VEGF-A (n  5) and Mel57-VEGF-
A/Sema3E (n  5) tumors using TRIzol reagent (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s pro-
tocol and treated with DNaseI (NEB, Ipswich, MA). RNA
samples (1 g) were reverse transcribed using MMLV re-
verse transcriptase (Promega, Leiden, The Netherlands)
according to the manufacturer’s instructions. In each in-
dividual sample, cDNA quality was assessed by PCR for
-actin and VEGF-A. Of each tumor group, cDNAs were
pooled and subjected to the human extracellular matrix
and adhesion molecules RT2 profiler array (Superarray
Bioscience Corporation, Frederick, MD). Amplification
was performed in a volume of 25 l containing 1 l of
template cDNA, 12.5 l of RT2 real-time SYBR Green/
ROX PCR master mix, 10.5 l of H2O, and 1 l RT
2 primer
set. Amplification was performed for 40 cycles (95°C for
15 seconds, 60°C for 1 minute) on an ABI 7000 Real-Time
PCR System (Applied Biosystems, Foster City, CA). For
data analysis the 2Ct method28 was used with nor-
malization of raw data to the housekeeping gene glycer-
aldehyde-3-phosphate dehydrogenase. Fold change val-
ues are presented as difference in expression due to
Sema3E-overexpression in Mel57-VEGF xenografts. Cut
off values for significant up- or down-regulation were
chosen as 3 and 0.3, respectively.
Results
PLXND1 and Sema3E Expression in Human
Melanocytic Lesions
(Dysplastic) Naevi
We analyzed PLXND1 and Sema3E expression in benign
melanocytic lesions, primary melanomas of different
stage, and melanoma metastases to determine whether
this receptor/ligand couple could be involved in tumor
progression. As shown by immunohistochemistry with
single domain antibody A12, PLXND1 expression was
absent in melanocytes in both naevocellular naevi and
dysplastic naevi (Figure 1, A and B respectively). Further-
more, no vessel-associated PLXND1 expression was ob-
served in naevi. In the majority of naevi, we observed
immunoreactivity on cells that appeared to be subsets of
macrophages (arrow in Figure 1A) as determined by CD68
Figure 1. Immunohistochemical analysis of PLXND1 and Sema3E expression
in naevi. PLXND1 is not detected in melanocytes in naevocellular (A) and
dysplastic (B) naevi. Note the PLXND1-positivity of macrophage- (arrow in
A) and fibroblast-like (arrowhead in A) cells. Melanocytes in naevocellular
(C) and dysplastic (D) naevi abundantly express Sema3E. Note that vessels in
a dysplastic naevus express Sema3E (arrows in D). Magnification  original
200 (A, B) and 100 (C, D).
PLXND1 and Sema3E in Tumor Progression 1875
AJP December 2008, Vol. 173, No. 6
staining (not shown) and fibroblast-like cells (arrowhead in
Figure 1A). Whereas PLXND1 was not expressed by mela-
nocytes, Sema3E was abundantly expressed in melano-
cytes, in approximately 80% and 75% of the naevocellular
(Figure 1C) and dysplastic (Figure 1D) naevi, respectively.
The vasculature in all but one dysplastic naevi also stained
positive for Sema3E (arrows in Figure 1D).
Primary Cutaneous Melanoma
Tumor cells in melanomas in situ were negative for
PLXND1 (Table 1). However, 73% of the primary cutane-
ous melanomas exhibited membranous PLXND1 expres-
sion by tumor cells. The PLXND1 expression pattern var-
ied per tissue sample from focal to homogeneous
throughout the tumor. PLXND1 expression by tumor cells
increased during progression from Clark II to IV (Table 1),
with 43% of Clark II melanomas (Figure 2A) and 100% of
Clark IV melanomas (Figure 2B) showing tumor cell-as-
sociated PLXND1 to some extent. Also within tumors, the
percentage of PLXND1-positive melanoma cells in-
creased with Clark level (Table 1). In 40% of Clark IV
primary cutaneous melanomas, all tumor cells expressed
PLXND1 (Figure 2B). Whereas PLXND1 expression on
tumor cells correlated with Clark level, we did not find a
correlation between tumor cell PLXND1 expression and
tumor thickness according to the Breslow index. How-
ever, vascular expression of PLXND1 did increase with
tumor thickness. PLXND1-positive tumor vessels were
absent in primary cutaneous melanoma thinner than 2
mm, while 83% of the lesions (Clark IV melanomas)
thicker than 2 mm showed PLXND1-positive tumor ves-
sels (Table 2). The arrows in Figure 2B point at PLXND1-
positive tumor vessels in a Clark IV melanoma with a
Breslow thickness of 3.2 mm. Even in a Clark IV mela-
noma with a Breslow thickness of 0.65 mm, tumor vessels
were negative (arrow in Figure 2C).
The increase in PLXND1 expression was not paralleled
by Sema3E expression, which was not significantly dif-
ferent between Clark II, III, and IV melanomas (Table 3).
The inset in Figure 2B shows an example of a PLXND1-
positive Clark IV melanoma in which no Sema3E expres-
sion is detected. Interestingly, blood vessels in Clark II
(inset in Figure 2C) and Clark III melanomas stained
positive for Sema3E, whereas in Clark IV lesions Sema3E-
negative vessels were present too.
Melanoma Metastases
Approximately 90% of the melanoma metastases showed
PLXND1 immunoreactivity (Table 1). A homogeneous ex-
pression pattern on all melanoma cells was observed in
75% and 78% of the skin and lymph node (Figure 2D)
metastases respectively, while only one lymph node me-
tastasis showed focal PLXND1 expression by tumor cells
(not shown). Consistent with our earlier observations,
PLXND1 was abundantly expressed by both melanoma
Figure 2. PLXND1 expression in primary melanomas and a melanoma me-
tastasis as revealed by immunostaining with single domain antibody A12.
Shown are PLXND1 positive tumor cells in a Clark II melanoma (A), Clark IV
melanomas (B and C) and a lymph node metastasis (D). Note in B that tumor
vessels in a melanoma with a Breslow thickness of 3.2 mm express PLXND1
(arrows), while PLXND1 is absent in the vasculature of a Clark IV melanoma
with a Breslow thickness of 0.65 mm (arrow in C). The insets in B, C and D
show Sema3E staining in a Clark IV melanoma (B), a Clark II melanoma (C),
and a lymph node metastasis (D). Magnification  original 200 (A–D) and
100 (insets).
Table 1. Membranous PLXND1 Expression in Melanocytic Cells in Benign Naevi, Primary Cutaneous Melanomas, and Melanoma
Metastases
% Positive
melanocytic cells
Naevi
naevocellularis
Dysplastic
naevi
Melanomas
in situ
Primary melanomas Melanoma metastases
Clark II Clark III Clark IV Skin
Lymph
node Brain Lung
0 19 10 5 4 2 1 1
1–25 2 2
26–50 2 1
51–75 1 1
76–99 2 1 1
100 4 3 7 5 1
N/Nt* 0/19 0/10 0/5 3/7 3/5 10/10 3/4 8/9 5/5 1/1
% 0% 0% 0% 43% 60% 100% 75% 89% 100% 100%
*Number of PLXND1 positive lesions (N) per total number of examined lesions (Nt).
Table 2. PLXND1 Expression in Clark IV Melanomas
Breslow thickness
2 mm 2 mm
Melanoma cells 4 6
Tumor vasculature 0 5
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cells and tumor vessels in brain and lung metastases. In
contrast, both the number of melanoma metastases ex-
pressing Sema3E and the percentage of Sema3E-posi-
tive melanoma cells in individual lesions were reduced
compared to primary cutaneous melanomas (Table 3).
Only 36% of the melanoma metastases in our series
exhibited tumor cell expression of Sema3E, which further-
more was restricted to only a small number of melanoma
cells in 60% of these metastases. In 64% of the mela-
noma metastases, blood vessels were negative for
Sema3E whereas in the remaining 36%, Sema3E was
expressed in less than 25% of the tumor vessels.
Sema3E Inhibits VEGF-A-Induced Micronodular
Growth in Subcutaneous Angiogenic Melanoma
Xenografts
The unexpected inverse correlation between PLXND1
expression and its ligand Sema3E in melanoma progres-
sion series prompted us to examine whether expression
of Sema3E functionally affects tumor development and
metastatic behavior of VEGF-A-expressing subcutane-
ous Mel57 melanoma xenografts.26 In these xenografts,
tumor cells stain positive with our anti-PLXND1 single
domain antibody (Figure 3A). In addition, we analyzed
the effects of expression of Sema3C, the Neuropilin-1
dependent PLXND1 ligand, on tumor development and
metastasis of these subcutaneous xenografts. Mel57-
VEGF-A/Sema3E and Mel57-VEGF-A/Sema3C xeno-
grafts showed similar growth rates and developed some-
what delayed as compared to control Mel57-VEGF-A/
EGFP xenografts (Figure 3B). Mice were sacrificed when
tumors had reached comparable sizes. All mice exhibited
comparable elevated VEGF-A levels in their plasma (3
to 5 ng/ml) suggesting that effects on tumor growth,
morphology, and metastatic phenotype were due to
Sema3 expression and not to low VEGF-A production
by the tumor cells. In addition, VEGF-A expression in
the xenografts was confirmed by mRNA in situ hybrid-
ization (not shown). Sema3E and Sema3C expression
was determined by immunostaining on Mel57-VEGF-A/
Sema3E (inset in Figure 3C) and -/Sema3C (inset in
Figure 3E) xenografts respectively.
Whereas VEGF-A expressing Mel57 xenografts grew
with a characteristic micronodular phenotype,26 the ar-
chitecture of these tumors was remarkably different when
Sema3E was co-expressed (Figure 3C). Mel57-VEGF-A/
Sema3E xenografts consisted of a well vascularized rim
of viable tumor cells (Figure 3D), while centrally these
tumors were sparsely vascularized with numerous ne-
crotic areas. This phenotype was not observed when
Sema3C instead of Sema3E was co-expressed (Figure 3,
Table 3. Sema3E Expression in Melanocytic Cells in Benign Naevi, Primary Cutaneous Melanomas, and Melanoma Metastases
% Positive
melanocytic cells
Naevi
naevocellularis
Dysplastic
naevi
Melanomas
in situ
Primary melanomas Melanoma metastases
Clark II Clark III Clark IV Skin
Lymph
node Brain
0 2 1 1 1 1 2 5 2
1–25 1 2 2 1
26–50 1 1 1
51–75
76–99 1 1
100 8 3 4 3 3 3
N/Nt* 9/11 3/4 4/4 5/6 3/4 6/7 2/4 2/7 1/3
% 82% 75% 100% 83% 75% 86% 50% 29% 33%
*Number of Sema3E positive lesions (N) per total number of examined lesions (Nt).
Figure 3. Analysis of subcutaneous Mel57-VEGF-A xenografts co-expressing
Sema3E or Sema3C. A: PLXND1 expression in subcutaneous Mel57-VEGF-A
xenografts as revealed by immunohistochemistry using single domain anti-
body A12. Both Mel57-VEGF-A cells and endothelium express PLXND1 (the
inset shows a negative control staining with anti-VSV-G antibody). B: Tumor
growth curves of Sema3E (F) and Sema3C(Œ)-expressing Mel57-VEGF-A
xenografts and control Mel57-VEGF-A/EGFP lesions (). Tumor volumes are
calculated as height depthwidth. Note that the xenografts co-expressing
Sema3(C/E) show comparable growth rates. Histological analysis of subcu-
taneous Mel57-VEGF-A/Sema3E and -/Sema3C tumors by H&E staining (C
and E) and anti-CD34 staining (D and F). Note the absence of micronodular
transformation in Sema3E-expressing tumors (C and D), while Mel57-VEGF-A/
Sema3C xenografts show the typically VEGF-A induced micronodular growth
pattern (E and F). In contrast to Mel57-VEGF-A/Sema3C xenografts, Sema3E-
expressing tumors only show a well vascularized tumor rim. The insets in C and
E show Sema3E and Sema3C immunostainings on Mel57-VEGF-A/Sema3E (C)
and -/Sema3C (E) xenografts respectively. Magnification  original 100 (A,
insets), 25 (C, E) and 50 (D, F).
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E and F). Staining for the proliferation marker Ki-67 with
mouse Ki-67-specific antibodies revealed that, although
Sema3E reduced tumor angiogenesis, VEGF-A-induced
proliferation of vascular cells in the tumor rim was unaf-
fected in Mel57-VEGF-A xenografts co-expressing Sema3E
(not shown).
Sema3E Reduces Metastatic Potential of
Subcutaneous Mel57-VEGF-A Xenografts
We previously established that Mel57-VEGF-A tumors
metastasize by shedding multicellular tumor fragments,
surrounded by vessel wall elements, into the circulation,
which eventually grow to large lung tumors, initially in
pulmonary arteries.26 The multicellular origin of these
metastases was assessed by tagging tumor xenografts
with EGFP-expressing tumor cells. This principle was
also applied in the current experiments.
To investigate whether Sema3E affects metastatic ca-
pacity of Mel57 xenografts, we analyzed metastatic bur-
den, composition, and localization of lung lesions. In
mice carrying subcutaneous Mel57-VEGF-A/Sema3E
xenografts, metastatic load in the pulmonary vessels was
significantly reduced compared to Mel57-VEGF-A/EGFP
(P  0.022) and -/Sema3C tumors (P  0.006) (Figure
4A). WhereasMel57-VEGF-A/Sema3C xenografts exhibited
the typical metastatic features previously described for
Mel57-VEGF-A tumors26 (Figure 4B), such phenotype was
observed in only one mouse carrying a Mel57-VEGF-A/
Sema3E xenograft. In two mice of the Sema3E group,
small lung lesions in the tip of the lungs were detected
(Figure 4C), which in contrast to lung metastases derived
from Mel57-VEGF-A/Sema3C xenografts, lacked cover-
age by the vessel wall elements laminin (not shown) and
endothelial cells (inset in Figure 4C).
Because we co-injected EGFP-tagged Mel57 cells, we
could judge whether metastases were of multicellular or
monoclonal origin. EGFP immunostaining revealed that
the composition of most lung lesions derived from Mel57-
VEGF-A/Sema3C xenografts was polyclonal with both
Mel57-VEGF-A/Sema3C and Mel57-EGFP cells (Figure
4D), whereas the two Mel57-VEGF-A/Sema3E derived
lesions located in the lung tip were composed of EGFP
negative tumor cells (Figure 4E), suggesting that these
originated from clonal expansion of single tumor cells
rather than tumor emboli.
Subcutaneous Mel57-VEGF-A/Sema3E
Xenografts Display Down-Regulated Expression
of Thrombospondin 1 and Extracellular Matrix
Protein 1
Both angiogenesis and metastasis highly depend on ex-
tracellular matrix remodeling and establishing and dis-
rupting cell-cell interactions. We therefore compared ex-
pression profiles of a number of extracellular matrix and
adhesion molecules in Mel57-VEGF-A and Mel57-VEGF-A/
Sema3E tumors using the Superarray RT2 profiler kit. De-
tectable PCR products, defined as requiring 30 cycles,
were obtained for 41 out of 83 genes analyzed.
Neither of the tested genes were significantly up-reg-
ulated in tumors expressing Sema3E as compared to
Mel57-VEGF-A tumors. However, we found that throm-
bospondin 1 (THBS1) and extracellular matrix protein 1
(ECM1) were expressed at significantly lower levels (re-
spectively 3.8- and 3.6-fold lower as compared to Mel57-
VEGF-A xenografts, Figure 5A).
To validate the RT-PCR array results we examined
THBS expression at the protein level using immunohisto-
chemistry on frozen sections of Mel57-VEGF-A and
Mel57-VEGF-A/Sema3E tumors. In accordance with our
array data, these immunostainings revealed that THBS is
abundantly expressed in Mel57-VEGF-A xenografts (Fig-
ure 5B), but hardly detectable in Mel57-VEGF-A/Sema3E
tumors (Figure 5C). Note that our staining protocol, using
a mouse monoclonal THBS antibody, inevitably also re-
sults in non-specific staining of mouse IgG in necrotic
areas in both tumors (see negative control stainings with
anti-mouse secondary antibody only, insets). Compari-
son with these control stainings clearly shows that THBS
is associated with the network of vessel wall elements in
Mel57-VEGF-A lesions. Importantly, in these xenografts
THBS is expressed by Mel57-VEGF-A cells (magnifica-
tion in B), while tumor cells overexpressing Sema3E lack
THBS expression (magnification in C).
Figure 4. Analysis of metastatic burden, localization and composition. A:
Metastasic count of mice carrying different subcutaneous Mel57-VEGF-A
xenografts. Lung lesions were counted after H&E staining. Note that in mice
carrying subcutaneous Mel57-VEGF-A/Sema3E xenografts metastatic burden
is significantly reduced compared to Mel57-VEGF-A/EGFP (P  0.022) and
-/Sema3C tumors (P  0.006). In contrast, metastatic load in mice carrying
Sema3C expressing tumors is not significantly different from Mel57-VEGF-A/
EGFP xenografts (P  0.289). Histochemical analysis of lung metastases by
H&E staining (B and C) and anti-CD34 staining (insets) show that lung
metastases derived from Mel57-VEGF-A/Sema3C xenografts (B) are predom-
inantly located in the larger branches of the pulmonary vessels. Note in C that
the small lesion in the tip of the lung derived from a Mel57-VEGF-A/Sema3E
tumor is not surrounded by endothelial cells (inset in C). EGFP immuno-
staining on lung metastases derived from Mel57-VEGF-A/Sema3C (D) and
-/Sema3E (E) xenografts tagged with EGFP-expressing tumor cells. Note that
most lung metatases derived from Mel57-VEGF-A/Sema3C xenografts are of
multicellular origin with both Mel57-VEGF-A/Sema3C and Mel57-EGFP cells
(D), while the EGFP-negative lung lesion in mice carrying a subcutaneous
Mel57-VEGF-A/Sema3E xenograft likely originates from clonal expansion of
a single tumor cell (E). Magnification  original 50 (B) and 100 (C, D, E,
insets).
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Discussion
Previous studies have suggested a functional role of
PLXND1 in developmental angiogenesis.19,20 In later
stages of embryonic development, endothelial cells lose
PLXND1 expression and expression is absent in adult
endothelial cells.18 We demonstrated that PLXND1 is re-
expressed on vasculature during tumor-associated an-
giogenesis in both animal tumor models and a number of
human brain tumors.21 Here we show that PLXND1 is
expressed by the tumor vasculature in primary melano-
mas thicker than 2 mm. Transition from micro- to deeply
invasive melanoma is accompanied by angiogenesis3,4
which augments vascular invasion of melanoma cells.29
Thus, our findings confirm our previous observation that
PLXND1 is expressed on angiogenic endothelium and
not in quiescent vasculature.
PLXND1 was also abundantly expressed by tumor
cells, including metastatic melanoma cells. The presence
of consensus motifs for Rac-Rho signaling in the intracel-
lular domain of PLXND118 is consistent with a possible
regulatory role in cellular migration and, thus, tumor
progression.
Here we show using a single domain antibody against
the most amino terminal part of PLXND1 that expression
of this protein in melanocytic lesions is indeed correlated
with malignancy stage, being absent in benign lesions
and ubiquitous in metastatic cancer. An inverse relation-
ship was observed with Sema3E, one of the PLXND1
ligands, which was largely absent in metastatic lesions.
The hypothesis that emerges from these data, that
Sema3E expression is linked to decreased metastatic
potential, could be validated in a functional melanoma
metastasis assay.
The role of Sema3E in tumor biology has been matter
of debate in the literature. Originally this protein was
discovered via array-analyses as being correlated to
metastatic mamma carcinoma.24 In a follow-up study,
Christensen et al showed by RT-PCR that Sema3E was
expressed by 69% of human mamma carcinoma metas-
tases and overexpression resulted in increased tumor
growth in lungs.30 It has to be realized however, that in
these experiments tumor cells were injected directly in
the circulation. The initial and possibly rate-limiting steps
of metastasis, invasive growth in extracellular matrix, and
entry into the vasculature were thus lacking in these
experiments.
An inhibitory role of Sema3E for cell migration has also
been described. Sema3E acts via PLXND1 to serve as a
chemorepellant for endothelial cells22,23 and inhibits neo-
angiogenesis in vivo.22 Sema4A, which binds to the same
region of PLXND1 as Sema3E, suppresses VEGF-A-me-
diated angiogenesis by down-regulating Rac-GTP-de-
pendent cytoskeletal rearrangement,22 and it is conceiv-
able that Sema3E has a similar mode of action. This
notion is supported by our finding that Mel57 xenografts
overexpressing Sema3E and VEGF-A display large areas
of central necrosis, consistent with poor angiogenesis.
Yet, in vasculature in vital parts of Mel57 VEGF-A/
Sema3E xenografts proliferating endothelial cells were
observed, indicating that VEGF-A was still able to acti-
vate VEGF receptors on endothelial cells. We previously
showed that metastasis from Mel57-VEGF-A xenografts
develop by bulging of tumor nodules into dilated vessels,
a process that is accompanied by gradual coverage of
these nodules by endothelial cells.26 For this process,
both endothelial proliferation and migration are indis-
pensable. Our data are therefore consistent with a model
in which lack of metastatic capacity is due to impaired
migration of endothelial cells.
The dualistic chemorepellant/chemoattractant proper-
ties that are contained within Sema3E appear to be con-
trolled by proteolytic processing, converting a repelling
full length Sema3E into an inducer of invasiveness.30 The
antibody used in our current study recognizes both full
length Sema3E and the p61 degradation product. The
absence of any immunoreactivity in metastatic cancer
cells thus places doubt on whether similar proteolytic
mechanisms are relevant for regulating Sema3E activity
in melanoma. It has recently been described that the
presence or absence of neuropilin may also be an im-
portant factor, determining the guidance properties of the
Sema3E/PLXND1 complex.31 Interestingly, immunostain-
ings on our melanoma progression series revealed that
Figure 5. Fold-changes in mRNA expression of extracellular matrix and
adhesion molecules in Sema3E overexpressing tumors relative to the control
subcutaneous Mel57-VEGF-A lesions as revealed by RT-PCR array analysis
(A). Columns represent fold changes in expression in Sema3E-expressing
tumors relative to subcutaneous Mel57-VEGF-A lesions. Upper columns
(	1.00) represent molecules whose mRNA expression is up-regulated, lower
columns (1.00) molecules whose expression is down-regulated. Immuno-
histochemical analysis of THBS expression in subcutaneous Mel57-VEGF-A (B)
and Mel57-VEGF-A/Sema3E xenografts (C). In contrast to Mel57-VEGF-A/
Sema3E lesions THBS is abundantly expressed in Mel57-VEGF-A tumors (the
insets show negative control staining with anti-mouse antibody). Note in B that
THBS expression is clearly associated with the network of vessel wall
elements and tumor cells. Magnification  original 50 (B, C, insets) and
400 (enlargements).
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membranous expression of neuropilin-1 was almost ex-
clusively observed in melanoma metastases and to a
much lesser extent in primary melanomas (not shown),
ruling out an involvement for neuropilin-1 in regulating
Sema3E activity.
To obtain more insight in the underlying mechanisms
of angiogenesis and metastasis inhibition by Sema3E, we
examined expression levels of a series of genes involved
in extracellular matrix remodeling and cell adhesion.
THBS1 and ECM1 were significantly down-regulated in
Sema3E overexpressing xenografts. It must be noted that
we examined gene expression in tumor xenografts con-
sisting of a mix of tumor and stromal cells. Although we
can therefore not determine to which cell types the dif-
ferences in gene expression can be attributed, validation
of the array results by immunohistochemistry revealed that
Sema3E overexpression results in lack of THBS expression
by Mel57 cells. THBS is a secreted protein that interacts
with different types of collagen32,33 and laminin.33 These
matrix proteins are major components of the vascular net-
work surrounding Mel57-VEGF-A tumor noduli,26 which ex-
plains the localization of THBS inMel57-VEGF-A xenografts.
Thus, our observations are in agreement with a model in
which THBS is secreted by Mel57-VEGF-A cells followed by
retention by vessel wall elements generating a bioreservoir
of THBS. It remains to be established which mechanisms
underlie down-regulation of THBS by Sema3E on the cellu-
lar level.
The role of THBS1 in tumor progression is controver-
sial. Whereas this protein is generally presented as an
angiogenesis inhibitor, it has also been reported that
THBS1 promotes melanoma invasiveness and metastasis
via modulation of melanoma-matrix interactions (for re-
view, see34). Interestingly, in clinical cutaneous melano-
mas, THBS1 expression correlates with microvessel den-
sity, tumor thickness, and the presence of vascular
invasion.35 Our results are thus in agreement with a pro-
angiogenic and pro-metastatic effects of THBS1 in mel-
anoma progression.
We also found ECM1 to be down-regulated in Sema3E
expressing Mel57 tumors. Expression of ECM1 is closely
associated with early stages of angiogenesis during em-
bryonic development and this protein has also been
shown to be expressed by tumor cells.36,36,37 Concor-
dant with our results, ECM1 expression is associated with
metastatic behavior.37
Several other class 3 semaphorins and plexins have
been found to affect tumor growth and invasion. Whereas
Sema3A, 3B, and 3F are described to be functional in-
hibitors of tumorigenesis and involved in inhibition of
tumor cell spread,38–40 binding of Sema4D to its high
affinity receptor plexin B1 contributes to invasive tumor
growth and metastasis via activation of Met and Ron
receptors.41,42 Although we showed here that PLXND1
expression is correlated with tumor invasion and metas-
tasis in melanoma progression series, we could not re-
veal which of its ligands functionally contributes to tumor
progression and metastasis. Overexpression of Sema3C,
one of the other PLXND1 ligands, did not affect metasta-
sis of Mel57 xenografts. In addition, immunostainings on
a number of human melanocytic lesions revealed that
Sema3C was equally expressed in both benign and ma-
lignant tissue samples (not shown). Taken together,
based on our data we consider it unlikely that binding of
Sema3C to a Neuropilin-1/PLXND1 complex contributes
to tumor progression.
The correlation between PLXND1 expression and level
of melanoma invasion makes this protein a potentially
valuable diagnostic marker. PLXND1 can aid to distin-
guish primary cutaneous melanomas from naevi with a
sensitivity of 73%. The observation that PLXND1 is ex-
pressed in both tumor vessels and tumor cells in mela-
noma metastases may also have therapeutic relevance
since the protein may be used for simultaneous targeting
of different tumor compartments of metastatic melano-
mas, ie, melanoma cells and the tumor vasculature.21
In conclusion, PLXND1 expression correlates with ma-
lignancy grade in tumors but the ligand responsible for
PLXND1 activation still has to be identified. Sema3E ex-
pression inhibits angiogenesis and metastasis in mela-
noma, possibly via down-regulation of matrix-associated
proteins such as thrombospondin 1 and extracellular matrix
protein-1. It remains to be elucidated whether Sema3E ex-
erts its effect by competitive inhibition of as yet unknown
activating PLXND1 ligands.
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